Efficacy of JAK1/2 Inhibition in Murine Myeloproliferative Neoplasms Is Not Mediated by Targeting Oncogenic Signaling

By
Emily Salmini
-
0
1450
Investigators developed two JAK2-V617F-driven myeloproliferative neoplasm mouse models harboring ruxolitinib resistance mutations.
[Nature Communications]
Abstract